Glycemic and Inflammatory status of Type2 Diabetes after Antiviral Therapy for HCV

Not Applicable

• Conditions: hepatitis C virus HCV; Nutritional, Metabolic, Endocrine; Diabetes T2

• Registration Number: PACTR201712002777310
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-17
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

100 Patients diagnosed with type 2 diabetes and HCV-GT4 and treated with two direct antiviral agents (DAAs) will be follow up at 1-baseline, 2-after treatment(12 wks) and 3-12 wks after the end of treatments

Exclusion Criteria

Patients with other infectious diseases, autoimmune disorders, asthma, eczema, allergies, thyroid diseases, kidney failure, liver decompensation and alcohol abuse will be excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The glycemic status (F. glucose, HbA1c, F. insulin, HOMA-IR) was improved after after antiviral treatments

Secondary Outcome Measures

Name	Time	Method
changes in IL1,6,-17,23 and Gluc T2 gene polymorphism in diabetic patients treated with DAAs.